The global Narcolepsy Drugs market size was estimated to be US$ 4.1 billion in 2021 and is expected to grow at a CAGR of 10.5% between 2023 to 2032.
Narcolepsy is a lifelong sleep condition characterized by abrupt uncontrolled sleep episodes or attacks. This disorder harms many aspects of a patient's life and can cause severe problems. As per the Narcolepsy Network report, only 25% of those suffering from the disorder get diagnosed globally. Due to a lack of understanding among patients and healthcare professionals, this condition is quite difficult to identify.
Factors such as family history, age, and earlier neurological issues are all possible causes of this disease. In terms of age, occurrences mostly take place between the ages of 15 and 36. The part of the brain regulating the circadian cycle is expected to have some dysfunction however the exact causes are not known as of now.
Depression and anxiety are frequent in persons with narcolepsy, and whether these are symptoms because of the disorder or the outcome of impaired quality of life is not yet determined. Lower levels of hypocretin, a protein regulating the sleep-wake cycle are implicated in type 1 narcolepsy and cataplexy patients. Furthermore, factors like stress, toxic chemical abuse, brain damage, old age, and infection are also perceived as factors for narcolepsy disorder.
The market is primarily influenced by an older population in need of medical treatment, an increase in the prevalence of narcoleptic disorders, changing lifestyles, and an increase in stress levels, which leads to narcolepsy conditions. Furthermore, rising research efforts, higher healthcare expenditure, and the availability of improved medical infrastructure are projected to propel the narcolepsy therapeutics business in the approaching years.
The rising incidence of narcolepsy increased understanding of sleep disorders as a result of narcolepsy educational campaigns and awareness programs, and the expanding prevalence of favourable reimbursement are the biggest factors driving the expansion of the global narcolepsy drugs market.
Furthermore, increasing disposable incomes and greater government spending on health care, particularly in developed countries, are likely to benefit the worldwide narcolepsy medications market during the forecast period. The adverse effects of narcolepsy drugs, as well as the possibility of delay or misdiagnosis, are the key disadvantages that may limit narcolepsy drug market growth throughout the projection period.
Several local, national, and international institutions and organizations have taken the initiative to provide relevant information regarding available narcolepsy treatment options to promote understanding of sleep disorders and the presence of medicines linked with narcolepsy. Such an awareness program may enable narcolepsy drugs market growth prospects throughout the projection period.
Circadian delays, increased fluctuation in sleep-wake cycles, online working habits, and unhealthy lifestyles are creating an increase in the diagnosis of sleep disorders which is also causing a rise in the detection of narcolepsy symptoms. Such a large diagnosis will cause increased prescription of narcolepsy drugs and the subsequent growth of this market.
Because of the lower consumption of narcolepsy drugs during the Covid-19 pandemic, there was a significant reduction in the growth of the narcolepsy drugs market. The impact of Covid-19-related constraints on narcolepsy drugs and reduced idiopathic hypersomnia enabled increased sleep duration, relaxed work routine, and better circadian management for many individuals which decreased central hypersomnia symptoms in idiopathic hypersomnia patients.
This had an impact on the expansion of narcolepsy therapies, as the population's need for narcolepsy drugs decreased as a result of getting enough sleep during the pandemic. However, increased economic pressure and psychological stress post-pandemic are resulting in decreased mental well-being across the globe which may increase clinicians' preference for narcolepsy drugs in case of sleep disorders.
Lack of awareness about treatment and diagnosis options in numerous emerging and developing nations could limit growth throughout the global narcolepsy drugs industry in the upcoming years. Other significant impediments to the expansion of the global narcolepsy drugs market are the low stability and poor sustainability of such drugs when compared to other therapies.
On the other hand, the increased number of programs and activities launched by various organizations to raise awareness about this condition and the availability of acceptable treatment approaches may drive rapid expansion in the overall usage of narcolepsy drugs and products in the future years.
The global Narcolepsy drugs market may be divided into five major regions: Asia Pacific, North America, South America, Europe, and the Middle East and Africa. In the past few years, North America has kept the dominant position in the overall narcolepsy drugs market.
This remarkable market orientation of the North American region in the global narcolepsy therapeutics market can be due to a variety of factors, including an increase in the region's research and development activities aimed at furthering the awareness of narcolepsy to develop better treatments.
Other key factors driving growth in the global narcolepsy drugs market comprise different partnerships between commercial organizations and academic institutions in the area, as well as an increase in new product releases, mergers, and product approvals.
Arena Pharmaceutical, Inc., Address Pharmaceuticals, Bioprojet Pharma SRL, GrayMark Healthcare Inc., Novartis AG., Jazz Pharmaceuticals Plc., Ligand Pharmaceuticals Inc, Shire Plc, Teva Pharmaceutical Industries Ltd., etc are some of the major players in the global narcolepsy drugs market.
By Disease Type
By Therapeutics Type
By Drug Type
By Development channels
By Geography
The narcolepsy drugs market is expected to grow at a CAGR of 10.5% between 2023 to 2032.
The covid-19 pandemic negatively impacted the growth of global narcolepsy drugs due to reduced demand for non-essential therapies and a reduction in the number of patients.
Arena Pharmaceutical, Inc., Addrenex Pharmaceuticals, Bioprojet Pharma SRL, GrayMark Healthcare Inc., Novartis AG., Jazz Pharmaceuticals Plc., Ligand Pharmaceuticals Inc, Shire Plc, Teva Pharmaceutical Industries Ltd., etc are some of the major players in the global narcolepsy drugs market.
The narcolepsy drugs market size was estimated to be US$ 4.1 billion in 2021
Narcolepsy drugs are used for the treatment of hypersomnia symptoms like Daytime Extreme Sleepiness, Cataplexia, etc.
The rising incidence of narcolepsy increased understanding of sleep disorders as a result of narcolepsy educational campaigns and awareness programs, and the expanding prevalence of favourable reimbursement are the biggest factors driving the expansion of the global narcolepsy drugs market.
Copyright © 2024 Same Page Management Consulting Pvt. Ltd. (insightSLICE) | All Rights Reserved